Company: ZLAB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001704292-25-000024
Chunk: 97

Company: Zai Lab Ltd
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 97
---
: 

•a decrease of $22.6 million in licensing fees in connection with decreased upfront and milestone payments for our license and collaboration agreements; and

•a decrease of $1.9 million in personnel compensation and related costs primarily driven by our resource prioritization and efficiency efforts; partially offset by

•an increase of $5.7 million in CROs/CMOs/Investigators expenses related to ongoing clinical trials.

 Research and development expenses decreased by $23.0 million in the nine months ended September 30, 2025 primarily due to a decrease of $14.6 million in personnel compensation and related costs and a decrease of $8.7 million in CROs/CMOs/Investigators expenses primarily driven by our resource prioritization and efficiency efforts.

23

The following table presents our research and development expenses by program ($ in thousands):

Three Months Ended September 30,ChangeNine Months Ended September 30,Change20252024$%20252024$%Clinical programs18,179 23,060 (4,881)(21)%63,236 63,196 40 — %Pre-Clinical programs1,982 14,461 (12,479)(86)%10,365 19,649 (9,284)(47)%Unallocated research and development expenses27,767 28,461 (694)(2)%85,670 99,407 (13,737)(14)%Total47,928 65,982 (18,054)(27)%159,271 182,252 (22,981)(13)%

Research and development expenses attributable to clinical programs decreased by $4.9 million in the three months ended September 30, 2025, primarily driven by a decrease in licensing fees for our license and collaboration agreements, partially offset by an increase in trial costs related to ongoing clinical trials. Research and development expenses attributable to clinical programs remained flat in the nine months ended September 30, 2025, primarily driven by an increase in licensing fees for our license and collaboration agreements, partially offset by decreases in trial costs due to our resource prioritization and efficiency efforts.

Research and development expenses attributed to preclinical programs decreased by $12.5 and $9.3 million in the three and nine months ended September 30, 2025, respectively, primarily driven by a decrease in licensing fees for our license and collaboration agreements. 

Although we manage our external research and development expenses by program, we do not allocate